Clonality analysis as a tool to study the biology and response to therapy in myelodysplastic syndromes

Leukemia

Volumn 11, Issue 5, 1997, Pages 660-666

  Schmetzer, H M ^a   Poleck, B ^a   Mittermuller J ^b   Duell, T ^a   Wilmanns, W ^a   Gerhartz, H H ^c  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Institute of Haematology   (Germany)

^c Hospital Duisburg North   (Germany)

Author keywords

Clonality; Cytogenetics; Myelodysplasia; Southern blot analysis

Indexed keywords

CYTARABINE; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 3;

ARTICLE; BONE MARROW CELL; CANCER CHEMOTHERAPY; CHROMOSOME MARKER; CLINICAL ARTICLE; CYTOGENETICS; GENE REARRANGEMENT; HUMAN; HUMAN CELL; LYMPHOCYTE CLONE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROGNOSIS; SOUTHERN BLOTTING; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

EID: 0030989713     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2400641     Document Type: Article

References (11)

1. Bennet JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51: 189-199.
2. Mufti GJ, Stevens JR, Oscier DC, Hamblin TJ, Machin D. Myelodysplastic syndromes: a scoring system with prognostic significance. Br J Haematol 1985; 59: 425-133.
3. De Witte T, Zwaan F, Hermans J, Vernant J, Kolb H, Vossen J, Lönneqvist B, Beelen D, Ferrant A, Gmür J, Liu Yin J, Troussard X, Cahn J, Van Lint M, Gratwohl A. Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndrome: a survey by the leukaemia working party of the European Bone Marrow Transplantation Group (EBMTG). Br J Haematol 1990; 74: 151-155.
4. Fenaux P, Morel P, Rose C, Lai JL, Jouet JP, Bauters F. Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy. Br J Haematol 1991; 77: 497-501.
5. Cheson BD, Jasperse DM, Simon R, Friedman MA. A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes. J Clin Oncol 1986; 4: 1857-1864.
6. Ganser A, Bartram CR, Ottmann OG, Seipelt G, Janssen JWG, Eder M, Becher R, Schulz G, Hoelzer G. Stimulating of non-clonal hematopoiesis in patients with hematological disorders by recombinant human GM-CSF or interleukin-3. Blood 1990; 76: 144a (Abstr.).
7. Broxmeyer HE, Cooper S, Williams DE, Hangoc G, Gutterman JU, Vadhan-Raj S. Growth characteristics of marrow hematopoietic progenitor/precursor cells from patients on a phase I clinical trial with purified recombinant human granulocyte-macrophage colony-stimulating factor. Exp Hematol 1988; 16: 594-602.
8. Brach M, Klein H, Platzer E, Mertelsmann R, Herrmann F. Effect of interleukin-3 on cytosine arabinoside-mediated cytotoxicity of leukemic myeloblasts. Exp Hematol 1990; 18: 748-753.
9. Yunis JJ, Lobell M, Arnesen MA et al. Refined chromosome study helps define prognostic subgroups in most patients with primary myelodysplastic syndrome and acute myelogenous leukaemia. Br J Haematol 1988; 68: 189-194.
10. Horike S, Taniwaki M, Schinichi M, Abe T. Chromosome abnormalities and karyotypic evolution in patients with myelodysplastic syndrome and predictive value for prognosis. Cancer 1988; 62: 1129-1138.
11. Janssen JWG, Buschle M, Layton M, Drexler HG, Lyons J, van den Berghe H, Heimpel H, Kubanek B, Kleihauer E, Mufti GJ, Bartram CR. Clonal analysis of myelodysplastic syndromes: evidence of multipotent stem cell origin. Blood 1989; 73: 248-254.